As of May 24, 2025, Viatris Inc (VTRS) reports a Gross Margin of 41.65%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Viatris Inc's Gross Margin
Over recent years, Viatris Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 41.65% |
| 2023-12-31 | 43.64% |
| 2022-12-31 | 43.25% |
| 2021-12-31 | 36.68% |
| 2020-12-31 | 38.02% |
This gradual decrease highlights how Viatris Inc manages its operational efficiency and pricing power over time.
Comparing Viatris Inc's Gross Margin to Peers
To better understand Viatris Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Viatris Inc (VTRS) | 41.65% |
| NGM Biopharmaceuticals Inc (NGM) | 7775.20% |
| Corcept Therapeutics Inc (CORT) | 98.39% |
| Innoviva Inc (INVA) | 89.80% |
| Supernus Pharmaceuticals Inc (SUPN) | 89.57% |
| Jazz Pharmaceuticals PLC (JAZZ) | 89.05% |
Compared to its competitors, Viatris Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.